Status:

COMPLETED

Therapeutics in Active Prostate Cancer Surveillance

Lead Sponsor:

CCTU- Cancer Theme

Collaborating Sponsors:

Janssen-Cilag Ltd.

Conditions:

Prostate Cancer

Eligibility:

MALE

18+ years

Phase:

PHASE2

Brief Summary

Testing if short-term use of apalutamide can reduce image defined tumour volumes in men with detectable lesion on multi-parametric Magnetic Resonance Imaging (mpMRI) and being managed by Active Survei...

Detailed Description

The numbers of men diagnosed with prostate cancer in the United Kingdom (UK) and worldwide is increasing. In the UK 46,690 men were diagnosed in 2014 alone and it is estimated this figure will be clos...

Eligibility Criteria

Inclusion

  • Given Informed Consent (IC) to participate
  • Age 18 or over
  • Eastern Cooperative Oncology Group (ECOG) status 0-2
  • Diagnosed with prostate cancer
  • Patient selection of active surveillance as a management option
  • mpMRI detectable lesion
  • Prostate cancer on biopsy from a mpMRI defined lesion
  • No contraindications to apalutamide
  • Normal full blood count and normal renal and liver function tests
  • At least 6 months since initiation of active surveillance and/or last rebiopsy date.
  • Low or intermediate risk prostate cancer according to National Institute for Health and Care Excellence (NICE) classification
  • M score of ≥ 3 using Prostate Imaging Reporting and Data System (PIRADS) version 2 reporting criteria

Exclusion

  • Contraindications to apalutamide or its excipients
  • Concurrent medication that can lower seizure threshold
  • Prior localised therapy for prostate cancer
  • Any prior use of androgen deprivation therapy or androgen receptor targeting agents
  • Any prior systemic therapy for prostate cancer
  • Patient unable to have prostate 3T mpMRI scan
  • Presence of any pelvic or hip metalwork

Key Trial Info

Start Date :

June 5 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 25 2019

Estimated Enrollment :

11 Patients enrolled

Trial Details

Trial ID

NCT03365297

Start Date

June 5 2018

End Date

July 25 2019

Last Update

November 19 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Cambridge University Hospitals NHS Foundation Trust/Addenbrookes Hospital

Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ